SCHEMBL386149

SCHEMBL386149

Cc1cc(-c2cc(-c3ccccc3OCC(C)C)[n+]([O-])cn2)ccc1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.38
ESR1 P03372 3/20 0.37
ESR2 Q92731 3/20 0.37
GCGR P47871 1/20 0.37
MAPK14 Q16539 1/20 0.37
PDE5A O76074 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
DHODH Q02127 2/20 0.35
CDC7 O00311 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CLK1 P49759 1/20 0.34
GSK3B P49841 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
CSNK2A3 Q8NEV1 1/20 0.34
TBXA2R P21731 1/20 0.34
PTGER1 P34995 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385739 0.90 IDO1 (0.43) PIM1ESR1ESR2CDC7CSNK2A2
SCHEMBL385438 0.87 PIM1 (0.41) PIM1ESR1ESR2GCGRMAPK14
SCHEMBL385119 0.86 IDO1 (0.41) PIM1CDC7CSNK2A2CLK1GSK3B
SCHEMBL383607 0.86 PIM1 (0.38) PIM1ESR1ESR2PDE5ACDC7
SCHEMBL383422 0.85 PIM1 (0.37) PIM1ESR1ESR2CDC7CSNK2A2
SCHEMBL385515 0.83 ESR1 (0.38) PIM1ESR1ESR2
SCHEMBL386324 0.79 PIM1 (0.53) PIM1ESR1ESR2CDC7CSNK2A2
SCHEMBL386224 0.75 PIM1 (0.67) PIM1ESR1ESR2GCGRMAPK14
SCHEMBL386297 0.74 TLR8 (0.37) ESR1ESR2MAPK14TLR8TP53
SCHEMBL386112 0.74 ESR1 (0.38) ESR1ESR2MAPK14TLR8TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101625-B2 Pyrimidinones as Casein Kinase II (CK2) modulators EXELIXIS, INC. (US) 2012-01-24 US disclosed
EP-1948617-B1 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS INC (US) 2011-07-27 EP disclosed
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators EXELIXIS, INC. 2009-08-27 US disclosed
EP-1948617-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS Exelixis, Inc. (US) 2008-07-30 EP disclosed
WO-2007048065-A2 PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215803-A1 Pyrimidinones as Casein Kinase II (CK2) Modulators CSNK2A1, CSNK1A1, CSNK2A2 PIM1 429/4885ESR1 1514/4885ESR2 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.